Bio Sequence

Biological Glossary | What is Enhancer?

3 November 2023
2 min read

Enhancers are one type of DNA sequence that has important functions in biology. Enhancers are regions or sequences found in DNA that promote the expression of certain other gene sequences. This means they play a crucial role in regulating gene expression. These enhancers interact with proteins, enzymes, and promotors to exert their influence on an organism's gene expression and promote the expression of certain gene sequences. Enhancers are essential to an organism's phenotype.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

图片包含 图示

描述已自动生成

Coherus and Junshi Biosciences reveal FDA validation for LOQTORZI™ (toripalimab-tpzi) in all treatment phases for repeated or spreading Nasopharyngeal Cancer (NPC)
Latest Hotspot
4 min read
Coherus and Junshi Biosciences reveal FDA validation for LOQTORZI™ (toripalimab-tpzi) in all treatment phases for repeated or spreading Nasopharyngeal Cancer (NPC)
3 November 2023
Coherus BioSciences, Inc. along with Shanghai Junshi Biosciences Co., Ltd. revealed that the FDA has given its approval for LOQTORZI™ (toripalimab-tpzi) to be used with cisplatin and gemcitabine.
Read →
Kymera Therapeutics starts Phase 2 trial of KT-474 (SAR444656), a new IRAK4 degrader, on its first Hidradenitis Suppurativa patient
Latest Hotspot
3 min read
Kymera Therapeutics starts Phase 2 trial of KT-474 (SAR444656), a new IRAK4 degrader, on its first Hidradenitis Suppurativa patient
3 November 2023
Kymera Therapeutics discloses initiation of Phase 2 trial with KT-474 (SAR444656), a novel IRAK4 degrader, being administered to its first Hidradenitis Suppurativa patient.
Read →
The Evolution of the Competitive Landscape Behind Regeneron's Pleasing Sales of High-dose Treatment for Macular Degeneration, Eylea
Bio Sequence
3 min read
The Evolution of the Competitive Landscape Behind Regeneron's Pleasing Sales of High-dose Treatment for Macular Degeneration, Eylea
3 November 2023
According to the Patsnap Bio Sequence Database, the top 10 applicants for the Aflibercept patent are Novartis with 80 applications, Regeneron with 60 applications, and Sanofi with 50 applications.
Read →
Lotilaner Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Lotilaner Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
8 November 2023
This article summarized the latest R&D progress of Lotilaner, the mechanism of action for Lotilaner, and the drug target R&D trends for Lotilaner.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.